Adolescent neuregulin 1 heterozygous mice display enhanced behavioural sensitivity to methamphetamine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 2, 2012, Pages 376-381

  Spencer, Jarrah R ^a   Darbyshire, Keturah M E ^a   Boucher, Aurelie A ^a   Arnold, Jonathon C ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

Adolescent; Locomotor activity; Methamphetamine; Neuregulin 1; PPI; Schizophrenia

Indexed keywords

METHAMPHETAMINE; NEU DIFFERENTIATION FACTOR;

ADOLESCENT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHILD PSYCHIATRY; CONTROLLED STUDY; DOSE RESPONSE; GENE FUNCTION; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY; HYPERACTIVITY; LOCOMOTION; MALE; MOUSE; NEUREGULIN 1 GENE; NONHUMAN; ONSET AGE; OPEN FIELD TEST; PREPULSE INHIBITION; REPEAT PROCEDURE; SCHIZOPHRENIA; SENSORY GATING; WILD TYPE;

AGE FACTORS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HETEROZYGOTE; MALE; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEUREGULIN-1; SENSORY GATING;

EID: 84867032229     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.07.014     Document Type: Article

References (41)

1. Abe Y., Namba H., Zheng Y., Nawa H. In situ hybridization reveals developmental regulation of ErbB1-4 mRNA expression in mouse midbrain: implication of ErbB receptors for dopaminergic neurons. Neuroscience 2009, 161:95-110.
2. Ago Y., Araki R., Yano K., Hiramatsu N., Kawasaki T., Chaki S., et al. Activation of metabotropic glutamate 2/3 receptors attenuates methamphetamine-induced hyperlocomotion and increase in prefrontal serotonergic neurotransmission. Psychopharmacology (Berl) 2011, 217:443-452.
3. Arnold J., Boucher A., Karl T. The yin and yang of cannabis-induced psychosis: the actions of {increment}9-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. Curr Pharm Des 2012, (Epub ahead of print).
4. Bossong M.G., Niesink R.J. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol 2010, 92:370-385.
5. Boucher A.A., Arnold J.C., Duffy L., Schofield P.R., Micheau J., Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology (Berl) 2007, 192:325-336.
6. Boucher A.A., Hunt G.E., Karl T., Micheau J., McGregor I.S., Arnold J.C. Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience 2007, 149:861-870.
7. Boucher A.A., Arnold J.C., Hunt G.E., Spiro A., Spencer J., Brown C., et al. Resilience and reduced c-Fos expression in P2X7 receptor knockout mice exposed to repeated forced swim test. Neuroscience 2011, 189:170-177.
8. Boucher A.A., Hunt G.E., Micheau J., Huang X., McGregor I.S., Karl T., et al. The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. Int J Neuropsychopharmacol 2011, 14:631-643.
9. Bousman C.A., Glatt S.J., Everall I.P., Tsuang M.T. Genetic association studies of methamphetamine use disorders: a systematic review and synthesis. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:1025-1049.
10. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997, 94:2569-2574.
11. Brosda J., Hayn L., Klein C., Koch M., Meyer C., Schallhorn R., et al. Pharmacological and parametrical investigation of prepulse inhibition of startle and prepulse elicited reactions in Wistar rats. Pharmacol Biochem Behav 2011, 99:22-28.
12. Chong V.Z., Thompson M., Beltaifa S., Webster M.J., Law A.J., Weickert C.S. Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients. Schizophr Res 2008, 100:270-280.
13. Dean B., Karl T., Pavey G., Boer S., Duffy L., Scarr E. Increased levels of serotonin 2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice. Schizophr Res 2008, 99:341-349.
14. Fusar-Poli P., Howes O.D., Allen P., Broome M., Valli I., Asselin M.C., et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 2011, 16:67-75.
15. Giedd J.N., Blumenthal J., Jeffries N.O., Castellanos F.X., Liu H., Zijdenbos A., et al. Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci 1999, 2:861-863.
16. Greenwood T.A., Lazzeroni L.C., Murray S.S., Cadenhead K.S., Calkins M.E., Dobie D.J., et al. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry 2011, 168:930-946.
17. Hadamitzky M., Markou A., Kuczenski R. Extended access to methamphetamine self-administration affects sensorimotor gating in rats. Behav Brain Res 2011, 217:386-390.
18. Hutchison K.E., Swift R. Effect of d-amphetamine on prepulse inhibition of the startle reflex in humans. Psychopharmacology (Berl) 1999, 143:394-400.
19. Ishiguro H., Horiuchi Y., Ishikawa M., Koga M., Imai K., Suzuki Y., et al. Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry 2010, 67:974-982.
20. Karl T., Duffy L., Scimone A., Harvey R.P., Schofield P.R. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav 2007, 6:677-687.
21. Karl T., Burne T.H., Van den Buuse M., Chesworth R. Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit?. Behav Brain Res 2011, 223:336-341.
22. Kato T., Abe Y., Sotoyama H., Kakita A., Kominami R., Hirokawa S., et al. Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Mol Psychiatry 2011, 16:307-320.
23. Kwon O.B., Paredes D., Gonzalez C.M., Neddens J., Hernandez L., Vullhorst D., et al. Neuregulin-1 regulates LTP at CA1 hippocampal synapses through activation of dopamine D4 receptors. Proc Natl Acad Sci USA 2008, 105:15587-15592.
24. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996, 93:9235-9240.
25. Li D., Collier D.A., He L. Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 2006, 15:1995-2002.
26. Lieberman J.A., Kane J.M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987, 91:415-433.
27. Long L.E., Chesworth R., Arnold J.C., Karl T. A follow-up study: acute behavioural effects of Delta(9)-THC in female heterozygous neuregulin 1 transmembrane domain mutant mice. Psychopharmacology (Berl) 2010, 211:277-289.
28. Long L.E., Chesworth R., Huang X.F., McGregor I.S., Arnold J.C., Karl T. Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. Int J Neuropsychopharmacol 2012, 1-13.
29. Malone D.T., Hill M.N., Rubino T. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol 2010, 160:511-522.
30. Marshall J.F., O'Dell S.J. Methamphetamine influences on brain and behavior: unsafe at any speed?. Trends Neurosci 2012, (Epub ahead of print).
31. Mei L., Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008, 9:437-452.
32. Munafo M.R., Thiselton D.L., Clark T.G., Flint J. Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol Psychiatry 2006, 11:539-546.
33. Quednow B.B., Frommann I., Berning J., Kuhn K.U., Maier W., Wagner M. Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia. Biol Psychiatry 2008, 64:766-773.
34. Ralph R.J., Varty G.B., Kelly M.A., Wang Y.M., Caron M.G., Rubinstein M., et al. The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J Neurosci 1999, 19:4627-4633.
35. Roussos P., Giakoumaki S.G., Adamaki E., Bitsios P. The influence of schizophrenia-related neuregulin-1 polymorphisms on sensorimotor gating in healthy males. Biol Psychiatry 2011, 69:479-486.
36. Roy K., Murtie J.C., El-Khodor B.F., Edgar N., Sardi S.P., Hooks B.M., et al. Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. Proc Natl Acad Sci USA 2007, 104:8131-8136.
37. Shen X., Purser C., Tien L.T., Chiu C.T., Paul I.A., Baker R., et al. mu-Opioid receptor knockout mice are insensitive to methamphetamine-induced behavioral sensitization. J Neurosci Res 2010, 88:2294-2302.
38. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 2000, 24:417-463.
39. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002, 71:877-892.
40. Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr Res 2008, 102:1-18.
41. van den Buuse M., Wischhof L., Lee R.X., Martin S., Karl T. Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. Int J Neuropsychopharmacol 2009, 12:1383-1393.